All In Biotech

Drug Trial Radar · NCT03367572

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

Last checked: Nov 19, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,363 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,363

Actual

Start

Apr 19, 2018

Primary completion

Apr 13, 2024

Study completion Apr 13, 2024

Sponsor

Lead sponsor
University of Rochester NCORP Research BaseAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Dec 8, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.

Conditions

  • Breast Carcinoma

Interventions

  • DexamethasoneDrug

    Given PO

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Netupitant/Palonosetron HydrochlorideDrug

    Given PO

  • OlanzapineDrug

    Given PO

  • PlaceboOther

    Given PO

  • ProchlorperazineDrug

    Given PO

  • Quality-of-Life AssessmentOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average Nausea Defined as the Average [ MAXIMUM ] Nausea Rating Across 15 Assessment Points at Cycle 1 and 16 Assessment Points at Cycle 2 (Comparing Prochlorperazine or Olanzapine to Control Arm)Time frame: Nausea measured at Cycle 1 Chemotherapy (15 time points which is Days 1,2,3,4) and also measured at Cycle 2 Chemotherapy (16 time points which is Days 1,2,3,4)
  2. Average Nausea Defined as the [AVERAGE] Nausea Rating Across 15 Assessment Points at Cycle 1 and 16 Assessment Points at Cycle 2 (Comparing Prochlorperazine or Olanzapine to Control Arm)Time frame: Nausea measured at Cycle 1 Chemotherapy (15 time points which is Days 1,2,3,4) and also measured at Cycle 2 Chemotherapy (16 time points which is Days 1,2,3,4)

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Hawaii MU NCORP

    Honolulu, Hawaii

  • Decatur Memorial Hospital

    Decatur, Illinois

  • Gulf South MU-NCORP

    New Orleans, Louisiana

  • Michigan Cancer Research Consortium

    Ann Arbor, Michigan

  • Cancer Research Consortium of West Michigan

    Grand Rapids, Michigan

  • Health Partners Inc

    Minneapolis, Minnesota

  • Cancer Research for the Ozarks NCORP

    Springfield, Missouri

  • Nevada Cancer Research Foundation NCORP

    Las Vegas, Nevada

  • University of Rochester NCORP Research Base

    Rochester, New York

  • Southeast Clinical Oncology Research Program

    Winston-Salem, North Carolina

  • Columbus NCORP

    Columbus, Ohio

  • Dayton Clinical Oncology Program

    Dayton, Ohio

  • Geisinger Cancer Institute NCORP

    Danville, Pennsylvania

  • Greenville NCORP

    Greenville, South Carolina

  • Upstate Carolina NCORP

    Spartanburg, South Carolina

  • Saint Vincent Hospital Cancer Center Green Bay

    Green Bay, Wisconsin

  • Gundersen Health System

    La Crosse, Wisconsin

  • Aurora NCORP

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.